Dependence of Technetium-99m Radioactivity on the Stability of Tc-99m Tetrofosmin as Injectable Radiopharmaceuticals
Widyastuti Widjaksana, Puji Widayati, Yunilda Alwi, Lindawati N
J. Pure App. Chem. Res. Vol 7, No 2 (2018), pp. 173-179
Submitted: November 29, 2017     Accepted: April 13, 2018     Published: May 12, 2018
DOI: http://dx.doi.org/10.21776/ub.jpacr.2018.007.02.397

Abstract


Cover Image

Technetium-99m (Tc-99m) labeled tetrofosmin kit has been widely used in hospitals including in Indonesia. Usually, tetrofosmin kits and Tc-99m pertechnetate are supplied separately, but recently there has been a new trend where Tc-99m tetrofosmin is supplied in the form of the ready-to-inject product. To prepare such a product it has to be proven that tetrofosmin can be labeled with high activity of Tc-99m and the resulted Tc-99m tetrofosmin, remains stable within shipping time until being used in hospitals. In this investigation, locally produced tetrofosmin kits were labeled with various radioactivity of Tc-99m ranging from 150 mCi to 400 mCi, their radiolabeling yields or radiochemical purity was analyzed using SepPak C18 column, and the radiochemical stability was assessed within 30 hours. The worst storage condition was also studied by analyzing its radiochemical purity after being stored at extreme temperatures for several hours. The results showed that tetrofosmin kit can be highly labeled with up to 415 mCi of Tc-99m, and stable up to 30 hours in room temperature, and there is a tendency that higher radioactivity leads to more decreasing in radiochemical purity. Stability study in extreme temperatures showed that the product can withstand its stability within 6 hours in 40°C, but it decreased rapidly to less than 70% within 1 hour when stored in 50°C. It concludes that the quality of Tc-99m tetrofosmin as an injectable radiopharmaceutical can be maintained during transportation by storing it at cool temperature.


Keywords : Tc-99m, tetrofosmin, injectable radiopharmaceuticals, radiochemical purity, stability.
Full Text: PDF


References


[1] Kartamihardja, H.S, Hasan Sadikin General Hospital, Personal Communication. 2011.

[2] G. A. Alexiou, X. Xourgia, E. Vartholomatos, S. Tsiouris, J. A. Kalef-Ezra, A. D. Fotopoulos, and A. P. Kyritsis, Int. J. Mol. Imaging, 2014, 2014, 1-5.

[3] C. Sioka, T. Exarchopoulos, I. Tasiou, E. Tzima, N. Fotou, A. Capizzello, V. Ragos, P. Tsekeris and A. Fotopoulos, Radiat. Oncol., 2011, 6, 151.

[4] K. Romanidis, E. Karathanos, E.A. Nagorni, A. Giatromanolaki, E. Sibridis, A. Zissimopoulos, T. Vogiatzaki, C. Simopoulos and M. Pitiakoudis, BMC Research Notes, 2014, 7, 335.

[5] V. Valotassiou, A. Leondi, G. Angelidis, D. Psimadas, and P. Georgoulias, The Scientific World Journal, 2012(2012), 1-11.

[6] Ashfaq Mahmood and Alun G. Jones, Technetium Radiopharmaceuticals, Handbook of Radiopharmaceuticals : Radiochemistry and Applications, Willey & Sons, England, 2003, 323-362.

[7] Gopal, B. S., Fundamentals of Nuclear Pharmacy, Springer Science+Business Media, LLC (2010) USA, 2010, 6th Ed.

[8] J. D. Kelly, A. M. Forster, B. Higley, C. M. Archer, F.S. Booker, L.R. Canning, K.W. Chiu, B. Edwards, H. K. Gill, M. McPartlin, J. Nucl Med 1993, 34(2), 222-227.

[9] W. Acampa, C. Di Benedetto and A. Cuocolo, J. Nucl Cardiol, 2000, 7(6), 701-707.

[10] Widyastuti, Sri Setyowati, Cecep Taufik Rustendi, Yunilda, J. Radioisotopes and Radiopharmaceuticals, 2012, 15(2), 70-78.

[11] Widyastuti, C. T. Rustendi, A. Roseliana, Jakaria, Karyadi, S. Aguswarini, and Sri Setyowa, Proceeding of National Seminar on Chemistry, Yogyakarta National University, Yogyakarta, 16 November 2013, pp. 131-137.

[12] GE Healthcare, Myoview package insert. 2006.

[13] N. E. Rosilawati, A. H. S. Kartamihardja, and A. Mutalib, IJAS, 2014, 4(1) 36-40.

[14] D. Murphy, Radiat. Protect. Management, 2003, 20(5) 18-27.

[15] L. Xiande and P. Linghua, Journal of Nuclear Agricultural Sciences, 2012, 26(5), 786-791.

[16] G. Abuhanoglu and A. Y. Ozer, Interventional Medicine & Applied Science, 2014, 6(2), 51-60.

[17] C. B. Silva, T. D. D. V. Araújo, P. R. L. Vasconcelos, H. C. B. D. Paula, N. A. P. Nogueira, C. A. B. D. O. Lira, G. M. Bastos, D. J. Woods, M. M. D. F. Fonteles, Int J Pharm Pharm Sci, 2015, 7(6) 129-135.

[18] Z. Irawati and Y. Sani, Nat. Sci., 2012, 4(2), 116-122.

[19] R.F.F. Vieira, D.T. Nardi, N. Nascimento, J. C. Rosa, C.R. Nakaie, Biol. Pharm. Bull., 2013, 36(4), 664-675.

[20] W. Jia, Y. He, Y. Ling, D. Hei, Q. Shan, Y. Zhang, J. Li, RAPC, 2015, 109(17), 17-22.

[21] Anonymous, USP 35, 2012.

[22] R. Hammes, L. A. Joas, Thomas E. Kirschling, J. R. Ledford., T. L. Knox, M. R. Nybo, and J. J. Sterzinger, J Nucl Med Technol, 2004, 32(2), 72-78.

[23] I. Zolle, Technetium-99m Pharmaceuticals : Preparation and Quality Control in Nuclear Medicine, Springer. 2007.

[24] IAEA Technical Reports Series No. 466, IAEA, Vienna, 2008. 129-132.


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.